ArticleUrology research & practice2026
Beyond the Rotisserie: Dispelling the Myths of Intravesical Therapy and Pioneering a Precision Future for Bladder Cancer.
Article in Urology research & practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the treatment of intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC), intravesical therapy with Bacillus Calmette-Guérin or chemotherapy remains the gold standard. However, traditional methods involving patient repositioning and catheter retention lack robust evidence. A focused narrative review of international guidelines (European Association of Urology, American Urological Association, Canadian Urological Association) and PubMed-indexed literature was conducted to address the rationale, efficacy, and pharmacokinetics of intravesical delivery, with particular attention to patient rotation and catheter management. Available evidence does not demonstrate a clinically meaningful benefit of routine post-instillation patient rotation for intravesical therapy. Major international guidelines do not recommend routine patient rotation during intravesical dwell time. Dwell times beyond 1 hour show diminishing incremental benefit, and prolonged catheter retention may limit uniform urothelial contact. Modeling studies suggest increased volume may enhance mucosal penetration but must be balanced with patient tolerance. Contemporary practices increasingly support immediate catheter removal following instillation. Emerging data suggest that tumor grade and biological features may complement traditional stagebased risk stratification. It was concluded that routine patient repositioning during intravesical treatment dwell time is not supported by evidence; no scheduled turns are required, thereby improving comfort and adherence. Immediate catheter removal after instillation may optimize urothelial exposure and improve patient tolerability, while potentially reducing catheter-associated complications. Clamped Foleys should be reserved for patients unable to voluntarily retain fluid and should be removed at the earliest opportunity. Advances in tumor grading, molecular characterization, and cautiously applied artificial intelligence tools may further refine risk stratification and personalize intravesical therapy in the future. Cite this article as: Khan MZ, Atta MA, Kotb A, Ismail A, Kotb A. Beyond the rotisserie: dispelling the myths of intravesical therapy and pioneering a precision future for bladder cancer. Urol Res Pract. 2026, 52, 0112, doi: 10.5152/tud.2026.25112.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.